Platelets in atherothrombosis - diagnostic and prognostic value of platelet activation in patients with atherosclerotic diseases

Current Vascular Pharmacology

Volumn 10, Issue 5, 2012, Pages 589-596

  Bigalke, Boris ^a,b   Schuster, Andreas ^b   Sopova, Kateryna ^c   Wurster, Thomas ^a   Stellos, Konstantinos ^c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

AMI; Antiplatelet therapy; Atherothrombosis; GPVI; Platelet activation; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ATOPAXAR; CLOPIDOGREL; GLYCOPROTEIN VI; PRASUGREL; TICAGRELOR; VORAPAXAR;

ACUTE HEART INFARCTION; ARTICLE; ATHEROSCLEROSIS; HUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROGNOSIS; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS;

ANIMALS; ARTERIAL OCCLUSIVE DISEASES; ATHEROSCLEROSIS; BLOOD PLATELETS; DRUG THERAPY, COMBINATION; HUMANS; MYOCARDIAL INFARCTION; PERIPHERAL ARTERIAL DISEASE; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; STROKE; THROMBOSIS;

EID: 84864536401     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016112801784468     Document Type: Article

References (84)

1. Bigalke, Krämer BF, Seizer P, Fateh-Moghadam S, Gawaz M, Lindemann S. Diagnostic and therapeutic potentials of platelet glycoprotein VI. Semin Thromb Hemost 2010; 36: 203-11.
2. Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res 2004; 61: 498-511.
3. Bigalke B, Pohlmeyer I, Schönberger T, et al. Imaging of injured atherosclerotic arteries in mice using fluorescence-labeled glycoprotein VI-Fc. Eur J Radiol 2011; 79: e63-9.
4. Bigalke B, Lindemann S, Schönberger T, et al. Ex vivo imaging of injured arteries in rabbits using fluorescence-labeled glycoprotein VI-Fc. Platelets 2012; 23: 1-6.
5. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 8: 1227-34.
6. Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood 2007; 102: 449-61.
7. Morrow DA, Sabatine MS, Brennan ML, et al. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J 2008; 29: 1096-102.
8. Heeschen C, Dimmeler S, Hamm CW, et al.; CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348: 1104-11.
9. Montaner J, Fernandez-Cadenas I, Molina CA, et al. Poststroke Creactive protein is a powerful prognostic tool among candidates for thrombolysis. Stroke 2006; 37: 1205-10.
10. Gawaz M, Neumann FJ, Ott I, et al. Platelet activation and coronary stent implantation. Effect of antithrombotic therapy. Circulation 1996; 94: 279-85.
11. Stellos K, Bigalke B, Stakos D, et al. Platelet-bound P-selectin expression in patients with coronary artery disease: impact on clinical presentation and myocardial necrosis, and effect of diabetes mellitus and anti-platelet medication. J Thromb Haemost 2010; 8: 205-7.
12. Htun P, Fateh-Moghadam S, Tomandl B, et al. Course of platelet activation and platelet-leukocyte interaction in cerebrovascular ischemia. Stroke 2006; 37: 2283-7.
13. McEver RP. Role of selectins in leukocyte adhesion to platelets and endothelium. Ann NY Acad Sci 1994; 714: 185-9.
14. Bigalke B, Lindemann S, Ehlers R, et al. Expression of platelet collagen receptor glycoprotein VI is associated with acute coronary syndrome. Eur Heart J 2006; 27: 2165-9.
15. Bigalke B, Geisler T, Stellos K, et al. Platelet collagen receptor glycoprotein VI as a possible novel indicator for the acute coronary syndrome. Am Heart J 2008; 156: 193-200.
16. Bigalke B, Stellos K, Geisler T, et al. Expression of platelet glycoprotein VI is associated with transient ischemic attack and stroke. Eur J Neurol 2010; 17: 111-7.
17. Adams HP, Jr., Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41.
18. +progenitor cells in Alzheimer's disease. PloS one 2011; 6: e20286.
19. Laske C, Leyhe T, Stransky E, et al. Association of platelet-derived soluble glycoprotein VI in plasma with Alzheimer's disease. J Psychiatr Res 2008; 42: 746-51.
20. Laske C, Stellos K, Eschweiler GW, et al. Decreased CXCL12 (SDF-1) plasma levels in early Alzheimer's disease: a contribution to a deficient hematopoietic brain support? J Alzheimers Dis 2008; 15: 83-95.
21. Stellos K, Langer H, Daub K, et al. Platelet-derived stromal cellderived factor-1 regulates adhesion and promotes differentiation of human CD34+ cells to endothelial progenitor cells. Circulation 2008; 117: 206-15.
22. Stellos K, Bigalke B, Langer H, et al. Expression of stromal-cellderived factor-1 on circulating platelets is increased in patients with acute coronary syndrome and correlates with the number of CD34+ progenitor cells. Eur Heart J 2009; 30: 584-93.
23. Wurster T, Stellos K, Haap M, et al. Platelet expression of stromalcell-derived factor-1 (SDF-1): an indicator for ACS? Int J Cardiol 2011 [Epub ahead of print].
24. Stellos K, Ruf M, Sopova K, et al. Plasma levels of stromal cellderived factor-1 in patients with coronary artery disease: effect of clinical presentation and cardiovascular risk factors. Atherosclerosis 2011; 219: 913-6.
25. Wurster T, Stellos K, Geisler T, et al. Expression of stromal-cellderived factor-1 (SDF-1): a predictor of ischemic stroke? Eur J Neurol 2012; 19(3): 395-401.
26. Geisler T, Fekecs L, Wurster T, et al. Association of platelet-SDF-1 with hemodynamic function and infarct size using cardiac MR in patients with AMI. Eur J Radiol 2011 [Epub ahead of print].
27. Bigalke B, Stellos K, Weig HJ, et al. Regulation of platelet glycoprotein VI (GPVI) surface expression and of soluble GPVI in patients with atrial fibrillation (AF) and acute coronary syndrome (ACS). Basic Res Cardiol 2009; 104: 352-7.
28. Bigalke B, Stellos K, Stakos D, et al. Influence of platelet count on the expression of platelet collagen receptor glycoprotein VI (GPVI) in patients with acute coronary syndrome. Thromb Haemost 2009; 101: 911-5.
29. Bigalke B, Haap M, Stellos K, et al. Platelet glycoprotein VI (GPVI) for early identification of acute coronary syndrome in patients with chest pain. Thromb Res 2010; 125: e184-9.
30. Bigalke B, Stellos K, Geisler T, et al. Glycoprotein VI for diagnosis of acute coronary syndrome when ECG is ambiguous. Int J Cardiol 2011; 149: 164-8.
31. Bigalke B, Stellos K, Geisler T, Lindemann S, May AE, Gawaz M. Glycoprotein VI as a prognostic biomarker for cardiovascular death in patients with symptomatic coronary artery disease. Clin Res Cardiol 2010; 99: 227-33.
32. Geisler T, Langer H, Wydymus M, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006; 27: 2420-5.
33. Geisler T, Bigalke B, Schwab M. CYP2C19 genotype and outcomes of clopidogrel treatment. N Engl J Med 2011; 364: 481.
34. Ollikainen E, Mikkelsson J, Perola M, et al. Platelet membrane collagen receptor glycoprotein VI polymorphism is associated with coronary thrombosis and fatal myocardial infarction in middle-age men. Atherosclerosis 2004; 176: 95-9.
35. Bigalke B, Langer H, Geisler T, Lindemann S, Gawaz M. Platelet glycoprotein VI: a novel marker for acute coronary syndrome. Semin Thromb Hemost 2007; 33: 179-84.
36. Bigalke B, Pötz O, Kremmer E, et al. Sandwich immunoassay for soluble glycoprotein VI in patients with symptomatic coronary artery disease. Clin Chem 2011; 57: 898-904.
37. Bigalke B, Elvers M, Schönberger T, Gawaz M. Platelet and soluble glycoprotein VI-novel applications in diagnosis and therapy. Curr Drug Targets 2011; 12: 1821-30.
38. Mueller C, Neumann FJ, Hochholzer W, et al. The impact of platelet count on mortality in unstable angina/non-ST segment elevation myocardial infarction. Am Heart J 2006; 97: 1435-40.
39. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 352: 1685-95.
40. Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-94.
41. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992; 326: 242-50.
42. Ohashi Y, Kawashima S, Mori T, et al. Soluble CD40 ligand and interleukin-6 in the coronary circulation after acute myocardial infarction. Int J Cardiol 2006; 112: 52-8.
43. Bigalke B, Schwimmbeck PL, Haas CS, Lindemann S. Effect of interleukin-15 (IL-15) on the course of myocarditis in coxsackievirus B3-infected BALB/c mice. Can J Cardiol 2009; 25: e248-54.
44. Yen MH, Bhatt DL, Chew DP, et al. Association between admission white blood cell count and one-year mortality in patients with acute coronary syndromes. Am J Med 2003; 115: 318-21.
45. Kruk M, Karcz M, Przyluski J, et al. White blood cell count adds prognostic information to the thrombolysis in myocardial infarction risk index in patients following primary percutaneous coronary intervention (ANIN Myocardial Infarction Registry). Int J Cardiol 2007; 116: 376-82.
46. Mueller C, Neumann FJ, Perruchoud AP, Buettner HJ. White blood cell count and long term mortality after non-ST elevation acute coronary syndrome treated with very early revascularisation. Heart 2003; 89: 389-92.
47. Steg PG, Dorman SH, Amarenco P. Atherothrombosis and the role of antiplatelet therapy. J Thromb Haemost. 2011; 9 (Suppl 1): 325-32.
48. Hao PP, Zhang MX, Li RJ, et al. Clopidogrel 150 mg/day vs. 75 mg/day in patients undergoing percutaneous coronary interventions: a meta-analysis. J Throm Haemost 2011; 9: 627-37.
49. Dalen JE. Aspirin to prevent heart attack and stroke: what's the right dose? Ann J Med 2006; 119: 198-202.
50. Siller-Matula JM, Jilma B, Schrör K, Christ G, Huber K. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost 2010: 8: 2624-41.
51. Bhatt DL, Cryer BL, Contant CF, et al.; COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363: 1909-17.
52. Ma TK, Lam YY, Tan VP, Kiernan TJ, Yan BP. Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel. Pharmacol Ther 2010: 125: 249-59.
53. Bhindi R, Ormerod O, Newton J, Banning AP, Testa L. Interaction between statins and clopidogrel: is there anything clinically relevant? Q J Med 2008: 101: 915-25.
54. Wiviott SD, Braunwald E, McCabe CH, et al.; TRITON-TIMI 38 Investigators. N Engl J Med 2007; 357: 2001-15.
55. Wallentin L, Becker RC, Budaj A, et al.; PLATO Investigators. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-57.
56. Mousa SA, Jeske WP, Fareed J. Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist. Clin Appl Thromb Hemost 2010: 16: 170-6.
57. Andre P, Deguzman F, Haberstock-Debic H, et al. Thienopyridines, but not elinogrel, result in off-target effects at the vessel wall that contribute to bleeding. J Pharmacol Exp Ther 2011; 338: 22-30.
58. Bigalke B, Seizer P, Geisler T, Lindemann S, Gawaz M, May AE. Perioperative antiplatelet therapy in patients at high risk for coronary stent thrombosis undergoing non-cardiac surgery. Clin Res Cardiol 2009; 98: 335-9.
59. Bigalke B, Geisler T, Hövelborn T, May AE, Gawaz M. Management of perioperative stent thrombosis in patients undergoing surgery. Platelets 2010; 21: 578-82.
60. Massberg S, Konrad I, Bultmann A, et al. Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. FASEB J 2004; 18: 397-9.
61. Ungerer M, Rosport K, Bültmann A, et al. The novel anti-platelet drug Revacept (dimeric GPVI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general haemostasis in humans. Circulation 2011; 123: 1891-9.
62. Yoshida S, Sudo T, Niimi M, et al. Inhibition of collagen-induced platelet aggregation by anopheline antiplatelet protein, a saliva protein from a malaria vector mosquito. Blood 2008; 111: 2007-14.
63. Angiolillo DJ, Capodanno D, Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J 2010; 31: 17-28.
64. Van de Werf F. Inhibitors of the platelet thrombin receptor: will they live up to their promises? Circulation 2011; 123: 1833-5.
65. White HD. Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions. Am Heart J 2011; 161: 450-61.
66. Pierson R. Merck clot drug seen unfit for stroke, shares fall [Online]. 2011 Jan 13, [cited 2011]. Available from: http://www.reuters.com/article/2011/01/13/us-merck-idUSTRE70C4EH20110113.
67. O'Donoghue ML, Bhatt DL, Wiviott SD, et al.; LANCELOT-CAD Investigators. Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin-Coronary Artery Disease Trial. Circulation 2011; 123: 1843-53.
68. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999; 353: 227-31.
69. Clemetson KJ, Clemetson JM. Platelet GPIb complex as a target for anti-thrombotic drug development. Thromb Haemost 2008; 99: 473-9.
70. Spiel AO, Gilbert JC, Jilma B. von Willebrand factor in cardiocascular disease: focus on acute coronary syndromes. Circulation 2008; 117: 1449-59.
71. Cauwenberghs N, Meirig M, Vauterin S, et al. Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in non-human primates. Arterioscler Thromb Vasc Biol 2000; 20: 1347-53.
72. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 2007; 116: 2678-86.
73. Kiefer TL, Becker RC. Inhibitors of platelet adhesion. Circulation 2009; 120: 2488-95.
74. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011; 473: 317-25.
75. Fitzgerald DJ, Roy L, Catella F, et al. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983-9.
76. Scharf RE, Tomer A, Marzec UM, et al. Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. Flow cytometric detection. Arterioscler Thromb 1992; 12: 1475-87.
77. Tschoepe D, Schultheiss HP, Kolarov P, et al. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation 1993; 88: 37-42.
78. Schultheiss HP, Tschoepe D, Esser J, et al. Large platelets continue to circulate in an activated state after myocardial infarction. Eur J Clin Invest 1994; 24: 243-7.
79. Ott I, Neumann FJ, Gawaz M, et al. Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation 1996; 94: 1239-46.
80. Samaha FF, Hibbard C, Sacks J, et al. Density of platelet collagen receptors glycoprotein VI and alpha2beta1 and prior myocardial infarction in human subjects, a pilot study. Med Sci Monit 2005; 11: CR224-229.
81. Al-Tamimi M, Gardiner EE, Thom JY, et al. Soluble glycoprotein VI is raised in the plasma of patients with acute ischemic stroke. Stroke 2011; 42: 498-500.
82. Al-Tamimi M, Grigoriadis G, Tran H, et al. Coagulation-induced shedding of platelet glycoprotein VI mediated by factor Xa. Blood 2011; 117: 3912-20.
83. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
84. Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without STsegment elevation. N Engl J Med 2001; 345: 494-502.